Injury of cartilage of talus
Conditions
Interventions
control group:The control group received topical diclofenac diethylamine emulgel (Voltaren
Beijing Novartis Pharma Co., Ltd.
approval No. H19990291) for treatment. **Administration:** (A) The dose was determined according to the area of pain
typically, a 3–5 cm strip of diclofenac emulgel was applied. (B) The gel was gently rubbed into the skin to facilitate transdermal penetration to the affected site. (C) The medication was applied twic
30 days constituted one treatment course, and all patients completed one course.
observation group:On the basis of the control intervention, the treatment group additionally received *Yao–Ba–Chuo* manual therapy. The manual therapy was administered twice per week, with the treatme
Sponsors
Beijing University of Chinese Medicine Third Affiliated Hospita
Eligibility
Sex/Gender
All
Age
18 Years to 78 Years
Inclusion criteria
Inclusion criteria: (1) Patients of either sex, aged 18–78 years, will be recruited. (2) Recurrent chronic ankle pain and swelling of varying severity, with symptoms markedly aggravated after activity or weight-bearing, accompanied by joint catching, stiffness, and ankle instability. (3) On specialist physical examination, there is evident tenderness over the talar dome of the ankle. (4) Osteochondral lesion of the talus with an avulsed cartilage fragment without displacement, localized subchondral bone marrow edema, and no giant talar cyst. (5) Plain radiography shows no evidence of talar collapse. (6) Patients are willing and able to comply with treatment and follow-up examinations and have provided written informed consent.
Exclusion criteria
Exclusion criteria: (1) Patients with severe injury to the ankle ligaments or tendons; (2) Patients with abnormal sensory function of the foot/ankle or with local skin infection; (3) Patients with serious primary diseases involving the cardiovascular/cerebrovascular system, liver, kidneys, hematopoietic system, or with psychiatric disorders; (4) Patients with an allergic constitution or known allergy to the study medication or any of its components; (5) Patients who have participated in other clinical drug trials within the past month.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Ankle-Hindfoot Scale;Area of MRI lesion;Plantar stress distribution; | — |
Secondary
| Measure | Time frame |
|---|---|
| McGill Pain Questionnaire Score;Proprioception; | — |
Countries
China
Contacts
Public ContactChen zhaojun
Beijing University of Chinese Medicine Third Affiliated Hospital
Outcome results
None listed